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Two Balb/C mouse models of Candida infection were used to detect serum
interleukin-6 (IL-6) responses. The first model used systemic infection by Candida
albicans ATCC 10231 strain infected through the lateral tail vein of mice without any
specific pretreatment. The median Candida burdens of the kidneys were 1.5 × 106
CFU/ml 24 h postinoculation (p.i.) and 1.2 × 107 CFU/ml 72 h p.i., while median se-
rum IL-6 levels were 479.3 pg/ml and 934.5 pg/ml, respectively. The Candida burden
showed significant correlation with serum IL-6 24 h p.i. (R2 = 0.6358; P = 0.0082) but
not 72 h p.i.
The second model was a mouse vaginitis model applying intravaginal inocula-
tion of mice pretreated with subcutaneous estradiol-valerate (10 mg/ml) 3 days before
infection. Candida cell count in vaginal lavage fluid was 2.8 × 106 CFU/ml 24 h p.i.
and 1.4 × 108 CFU/ml 72 h p.i. Serum IL-6 response was detected in 4 of 15 mice 24 h
p.i. and 9 of 15 mice 72 h p.i. Even the responders had low IL-6 serum levels (mean
values 29.9 pg/ml and 60.1 pg/ml, respectively) not correlating with Candida cell
count in vaginal lavage fluid.
In conclusion, serum IL-6 had strong relationship with systemic C. albicans
infection while the local C. albicans infection of the vagina led to partial, prolonged
and limited serum IL-6 response.
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Introduction
Candida albicans (C. albicans) is a permanent member of the human
microbiome and colonizes the human gastrointestinal, respiratory and reproduc-
tive tracts. However, when the host physiology is damaged (i.e. immuno-
suppressant therapy, diabetes mellitus) this fungal-host interrelationship can de-
generate and may lead to opportunistic fungal infections, which emerge as mu-
cosal or invasive fungal disease [1, 2].
Candida species are the fourth most frequent cause of healthcare-associ-
ated bloodstream infections in the hospital environment, which is associated with
high mortality (30–50%) [3]. On the basis of the ARTEMIS DISK 1997–2003 sur-
veillance program C. albicans is the most common species causing disseminated
candidiasis worldwide (66% of all Candida species) [3, 4]. According to last pub-
lished epidemiology data, comparable rate was observed at University of
Debrecen and at University of Szeged, C. albicans was identified in 58% and 64%
of Candida-positive blood culture, respectively [5, 6]. The major risk factors of
Candida-caused bloodstream infections are immunosuppressant therapy, broad-
spectrum antibacterial agents, prolonged use of catheters in intensive care unit as
well as different surgery interventions [4].
Vulvovaginal candidiasis (VVC) is a common mucosal infection caused by
different Candida species including C. albicans. Approximately 70–75% of
healthy women suffer at least one VVC episode during their childbearing age. In
the USA VVC is the second most common type of vaginal infections after bacte-
rial vaginitis. The most typical predisposing factors of VVC are disturbance in
hormone levels owing to pregnancy, antibiotic treatment, high-estrogen contra-
ceptive usage and uncontrolled diabetes mellitus [7, 8].
During the acute phase of infection, IL-6, a 22–30 kDa glycoprotein is se-
creted into the bloodstream and induces both B cell and T cell differentiation as
well as production of antibodies and acute phase proteins [9–11]. Since host
cytokine response against Candida infection is poorly understood, a systemic and
a vaginal candidiasis mouse model were used to measure serum IL-6 responses.
Materials and Methods
In the course of experiments the strain C. albicans 10231 ATCC was used.
Balb/C immunocompetent female mice (19–22 g) were infected in our in vivo
models. The animals were maintained in accordance with the Guidelines for the
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Care and Use of Laboratory Animals. The experiments were approved by the Ani-
mal Care Committee of the University of Debrecen (permission no.: 12/2008).
During the examination two models were used (vaginal and systemic infec-
tion mouse model). Animals were divided into 3 major groups per models. In vagi-
nal infection model, 50 µl subcutaneous estradiol-valerate (10 mg/ml) was given
to all mice three days prior to infection [11–13].
Animals were infected intravenously through the lateral tail vein (200 µl of
infective inoculum) in case of systemic model [14]. In the systemic model the in-
fectious dose of C. albicans was 3 × 105 CFU/mouse based on our preliminary in-
vestigations. In the vaginal model, mice were infected intravaginally with 3 × 105
stationary-phase C. albicans cells in 50 µl volumes. Inoculum density was con-
firmed by plating serial dilution on Sabouraud agar plates. In case of systemic
mouse model the animals were sacrificed (cervical dislocation) after 24 h and
72 h, kidney pairs were removed and homogenized aseptically. Fungal tissue bur-
den was determined by quantitative culturing. The homogenates were diluted by
1 ml sterile saline and serial tenfold dilutions were made in saline, subsequently
plated onto Sabouraud dextrose agar and the colony count was determined after
48 h. The control mice did not receive infective inoculation [14].
At 24 h p.i. the first group of the mice of vaginal model was sacrificed and
flushed their vagina with sterile physiological saline (100 µl). Thereafter 50 µl
volumes was taken out from lavage fluid, serially diluted tenfold and plated onto
Sabouraud dextrose agar. This method was repeated after 72 h at the second group.
The third group (control mice) received just hormone treatment. Control mice
were investigated both at 24 h p.i. and 72 h p.i. All colony counts were determined
after 48 h culture on Sabouraud plates.
In case of both models, blood was taken in way of retro-orbital with Pasteur
pipette (0 h, 24 h and 72 h p.i.). The samples were centrifuged at 24 h after the col-
lection (5 minute 6000 × g). The serum was isolated from each sample and put into
sterile Eppendorf tubes. The serum samples were stored at –20°C.
The serum samples were measured by Luminex xMAP (Biomedica) with
mouse cytokine panel. The differences between groups were analyzed by
Mann–Whitney U-test. Chi-square for trend test was used to test increasing num-
ber of responders by time. The level of significance was set at P < 0.05.
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Results
IL-6 levels and systemic infection
At 24 h after intravenous C. albicans ATCC 10231 inoculation, the median
of cell count was 1.5 × 106 CFU/ml. The distribution of the Candida burden at 24 h
was characterized by 2 mice with kidneys remained sterile and 13 mice with
Candida cell count ranging 6 × 105–8.6 × 106 CFU/ml. An average 7.6-fold in-
crease was found in the infected kidneys compared with the starting inoculums
(Fig. 1).
Acta Microbiologica et Immunologica Hungarica 61, 2014
64 KOVÁCS et al.
Figure 1. Candida cell burden of mice kidneys (A) and IL-6 levels of serum (B) in systemic candidiasis.
At 24 h the two lowest IL-6 values (<100 pg/ml) belong to mice with kidneys remained sterile
A
B
24 h 72 h
24 h 72 h
At 72 h after intravenous C. albicans ATCC 10231 inoculation, the median
of cell count was 1.2 × 107 CFU/ml. All 15 mice revealed Candida infection in the
kidneys, the Candida cell count ranged from 5 × 105 CFU/ml to 2.7 × 107 CFU/ml.
An average 38-fold increase was found in the infected kidneys compared with the
starting inoculums. The increase in the Candida burden of the kidneys between
days 1 and 3 was significant (P = 0.002) (Fig. 1).
On day 0, the baseline serum IL-6 was below the detection level in all tested
mice as well as serum IL-6 levels of control mice remained below detection level
after either 24 h or 72 h observation. In mice inoculated with C. albicans, the se-
rum IL-6 level were markedly above the detection threshold both 24 h and 72 h p.i.
(44.2–1083.6 pg/ml at 24 h; 162.4–64841 pg/ml at 72 h). Nevertheless, the two
mice with sterile kidneys at 24 h p.i. had outlyingly low serum IL-6 levels. Be-
tween days 1 and 3, the IL-6 level of the serum had an average 20-fold increase (P
= 0.004) (Fig. 1). At 24 h correlation was observed between the Candida cell count
and IL-6 level (R2 = 0.6358, P = 0.0082). After 3 days of the infection, the correla-
tion disappeared in spite of the increasing trend of both markers (R2 = 0.20747)
(Fig. 2).
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Figure 2. Correlation between Candida cell count (CFU/ml) and IL-6 level (pg/ml)
in systemic candidiasis model at 24 h and 72 h
24 h R2 = 0.6358
72 h R2 = 0.20747
IL-6 levels and vaginal infection
At 24 h after intravaginal C. albicans ATCC 10231 inoculation, all 15 mice
was suffering from marked vaginal discharge, the median Candida cell count was
2.8 × 106 CFU/ml vaginal lavage fluid (range: 1 × 105–3 × 107 CFU/ml). An aver-
age 19.6-fold increase was detected in the lavage fluid compared with the starting
inoculums. At 72 h after vaginal C. albicans inoculation, the median of cell count
was 1.4 × 108 CFU/ml. All 15 mice revealed Candida infection in their vagina, the
Candida cell count ranged from 9.4 × 105 CFU/ml to 6.5 × 108 CFU/ml. On day 0,
the baseline serum IL-6 was below the detection level in all tested mice. At 24 h
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24 h 72 h
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detectable IL-6 level was observed above the threshold in 4 of 15 mice. At 72 h
this ratio was 9 out of 15. At 24 h and 72 h detectable IL-6 levels were not noticed
in control mice. The proportion of IL-6 responder mice significantly increased by
time of infection (P = 0.01). The ranges serum IL-6 levels of the responders to vag-
inal infection (15.6–44.2 pg/ml at 24 h p.i. and 15.6–184 pg/ml at 72 h p.i.) were
much lower than the levels measured in systemic infections (Fig. 3).
Discussion
C. albicans is one of the most common inhabitants of our microbiome. This
Candida species caused infections can emerge from mucocutaneous candidiasis
to life-threatening candidaemia [2, 3, 15].
During our investigations proinflammatory IL-6 cytokine response was de-
termined in case of systemic candidiasis and in Candida vaginitis mouse model. In
the course of C. albicans infection, some proinflammatory cytokines (IL-6,
TNF-a, IL-12) are essential for the efficient control of infection [7]. IL-6 induces
acute phase proteins increased secretion therefore it has a pivotal role for develop-
ment on proper innate immune response [7]. Romani et al. observed that IL-6 defi-
cient mice are more susceptible to disseminated candidiasis than wild-type mice
[16] suggesting that IL-6 production is fundamental in terms of protection [17].
In the background of two mice with sterile kidneys 24 h after intravenous
inoculation of C. albicans, we assume the role of time factor, i.e. the systemic in-
fection has not completely resulted in colonization of kidneys by this time in the
whole inoculated population. Systemic proliferation of C. albicans might have
been delayed in these two mice as indicated by serum IL-6 levels exceeding those
in single organ infected but scoring under the IL-6 levels of mice with kidney col-
onization. In the disseminated candidiasis model at 24 h the measured IL-6 level
correlated with the Candida cell count. By 72 h p.i., the serum IL-6 levels in-
creased further, however lost correlation with microbial burden. An explanation
for this phenomenon is that strong defence mechanisms might have interfered
with the microbial burden more efficiently by this time. Another possible explana-
tion is that the serum IL-6 levels by this time might be close to the individual maxi-
mum value. Steinshamn et al. investigating serum IL-6 level from 3h to 72 h p.i. in
their mouse model observed its peak at 24 h [18]. Comparable IL-6 level was ob-
served at 24 h in case of our disseminated candidiasis model. However, at 72 h our
measured IL-6 value was significantly higher compared with at 24 h measured
value. Presumably the reason of this phenomenon that our mice were infected in-
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travenously while Steinshamn et al. give the infected inoculum intraperitoneally
to mice [18].
In our VVC mouse model, significant IL-6 level increase was not measured
at 24 h. Presumably the reason of this phenomenon that the infection remained lo-
cal, therefore it could not trigger systemic immune response against C. albicans.
By 72 h the fungal vaginal burden and the measured IL-6 level further increased,
but the rates of increase were slower and lower compared with those in our sys-
temic mouse model.
In conclusion our VVC model was adjusted successfully. Serum IL-6 had
strong relationship with systemic C. albicans infection, while the local C. albicans
infection of the vagina led to partial, prolonged and limited serum IL-6 response.
Further in vivo experiments are needed to assess the role of different cytokines in
the course of mucocutaneous and systemic candidiasis.
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